JP4012819B2 - デアセチラーゼ阻害剤として有用なヒドロキサム酸誘導体 - Google Patents

デアセチラーゼ阻害剤として有用なヒドロキサム酸誘導体 Download PDF

Info

Publication number
JP4012819B2
JP4012819B2 JP2002526830A JP2002526830A JP4012819B2 JP 4012819 B2 JP4012819 B2 JP 4012819B2 JP 2002526830 A JP2002526830 A JP 2002526830A JP 2002526830 A JP2002526830 A JP 2002526830A JP 4012819 B2 JP4012819 B2 JP 4012819B2
Authority
JP
Japan
Prior art keywords
alkyl
aryl
cycloalkyl
heteroaryl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2002526830A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004509105A5 (cg-RX-API-DMAC10.html
JP2004509105A (ja
Inventor
ケネス・ウォルター・ベア−
マイケル・エイ・グリーン
ローレンス・ビー・ペレス
ステイシー・ダブリュー・レミゼウスキー
リディア・サンブセッティ
リチャード・ウィリアム・バーセイス
スーシル・クーマー・シャルマ
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26923760&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4012819(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2004509105A publication Critical patent/JP2004509105A/ja
Publication of JP2004509105A5 publication Critical patent/JP2004509105A5/ja
Application granted granted Critical
Publication of JP4012819B2 publication Critical patent/JP4012819B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ceramic Engineering (AREA)
  • Health & Medical Sciences (AREA)
  • Manufacturing & Machinery (AREA)
  • Veterinary Medicine (AREA)
  • Structural Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2002526830A 2000-09-01 2001-08-30 デアセチラーゼ阻害剤として有用なヒドロキサム酸誘導体 Expired - Lifetime JP4012819B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22994300P 2000-09-01 2000-09-01
US29223201P 2001-05-18 2001-05-18
PCT/EP2001/010037 WO2002022577A2 (en) 2000-09-01 2001-08-30 Hydroxamate derivatives useful as deacetylase inhibitors

Publications (3)

Publication Number Publication Date
JP2004509105A JP2004509105A (ja) 2004-03-25
JP2004509105A5 JP2004509105A5 (cg-RX-API-DMAC10.html) 2007-10-04
JP4012819B2 true JP4012819B2 (ja) 2007-11-21

Family

ID=26923760

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002526830A Expired - Lifetime JP4012819B2 (ja) 2000-09-01 2001-08-30 デアセチラーゼ阻害剤として有用なヒドロキサム酸誘導体

Country Status (35)

Country Link
US (5) US6552065B2 (cg-RX-API-DMAC10.html)
EP (2) EP1318980B1 (cg-RX-API-DMAC10.html)
JP (1) JP4012819B2 (cg-RX-API-DMAC10.html)
KR (1) KR100585484B1 (cg-RX-API-DMAC10.html)
CN (1) CN1300110C (cg-RX-API-DMAC10.html)
AR (1) AR035057A1 (cg-RX-API-DMAC10.html)
AT (1) ATE376999T1 (cg-RX-API-DMAC10.html)
AU (2) AU2001282129B2 (cg-RX-API-DMAC10.html)
BE (1) BE2015C062I2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0113669B8 (cg-RX-API-DMAC10.html)
CA (1) CA2420899C (cg-RX-API-DMAC10.html)
CY (2) CY1107839T1 (cg-RX-API-DMAC10.html)
CZ (1) CZ302707B6 (cg-RX-API-DMAC10.html)
DE (1) DE60131179T2 (cg-RX-API-DMAC10.html)
DK (1) DK1318980T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP034492A (cg-RX-API-DMAC10.html)
ES (1) ES2292610T3 (cg-RX-API-DMAC10.html)
FR (1) FR15C0086I2 (cg-RX-API-DMAC10.html)
HU (2) HU229796B1 (cg-RX-API-DMAC10.html)
IL (2) IL154574A0 (cg-RX-API-DMAC10.html)
LU (1) LU92890I2 (cg-RX-API-DMAC10.html)
MX (1) MXPA03001832A (cg-RX-API-DMAC10.html)
MY (1) MY136892A (cg-RX-API-DMAC10.html)
NL (1) NL300778I2 (cg-RX-API-DMAC10.html)
NO (2) NO324942B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ524365A (cg-RX-API-DMAC10.html)
PE (1) PE20020354A1 (cg-RX-API-DMAC10.html)
PL (1) PL221738B1 (cg-RX-API-DMAC10.html)
PT (1) PT1318980E (cg-RX-API-DMAC10.html)
RU (1) RU2302408C3 (cg-RX-API-DMAC10.html)
SI (1) SI1318980T1 (cg-RX-API-DMAC10.html)
SK (1) SK287609B6 (cg-RX-API-DMAC10.html)
TW (1) TWI286544B (cg-RX-API-DMAC10.html)
WO (1) WO2002022577A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200301423B (cg-RX-API-DMAC10.html)

Families Citing this family (461)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
PT1233958E (pt) 1999-11-23 2011-09-20 Methylgene Inc Inibidores de histona desacetilase
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
ATE310719T1 (de) 2000-09-29 2005-12-15 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine amidgruppe als hdac-inhibitoren
US7312247B2 (en) * 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
WO2003032921A2 (en) * 2001-10-16 2003-04-24 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
CA2461373A1 (en) * 2001-11-06 2003-05-15 Novartis Ag Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
RU2394022C2 (ru) 2002-03-04 2010-07-10 МЕРК ЭйчДиЭйСи Рисерч, ЛЛС Способы индукции конечной дифференцировки
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
NZ536116A (en) 2002-04-03 2007-01-26 Topotarget Uk Ltd Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
WO2003087066A1 (en) * 2002-04-11 2003-10-23 Sk Chemicals, Co., Ltd. α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
AU2003226408B2 (en) * 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
CN101816792A (zh) * 2002-06-10 2010-09-01 诺瓦提斯公司 包含埃坡霉素的组合及其药学用途
JP4804004B2 (ja) * 2002-08-20 2011-10-26 アステラス製薬株式会社 関節軟骨細胞外マトリクス分解阻害剤
JP2006501267A (ja) * 2002-09-13 2006-01-12 バージニア コモンウェルス ユニバーシティー 白血病の処置のためのａ）Ｎ−｛５−［４−（４−メチル−ピペラジノ−メチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリミジン−アミンおよびｂ）ヒストンデアセチラーゼインヒビターの組合せ剤
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20060223826A1 (en) * 2002-11-19 2006-10-05 Takeda Pharmaceutical Company Limited Intellectual Property Department Indole derivatives as somatostatin agonists or antagonists
AU2003296310A1 (en) 2002-12-06 2004-06-30 University Of South Florida Histone deacetylase inhibitor enhancement of trail-induced apoptosis
US7135493B2 (en) 2003-01-13 2006-11-14 Astellas Pharma Inc. HDAC inhibitor
CA2513246A1 (en) 2003-01-17 2004-08-05 Topotarget Uk Limited Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors
AU2003900587A0 (en) * 2003-02-11 2003-02-27 Fujisawa Pharmaceutical Co., Ltd. Hdac inhibitor
AU2003900608A0 (en) * 2003-02-11 2003-02-27 Fujisawa Pharmaceutical Co., Ltd. Hdac inhibitor
WO2004076386A2 (en) 2003-02-25 2004-09-10 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
JP2006520796A (ja) 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
CA2526908A1 (en) * 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents
WO2005011598A2 (en) * 2003-07-31 2005-02-10 University Of South Florida Leukemia treatment method and composition
JP2007501775A (ja) * 2003-08-07 2007-02-01 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤
WO2005014004A1 (en) 2003-08-08 2005-02-17 Novartis Ag Combinations comprising staurosporines
PL379887A1 (pl) 2003-08-26 2006-11-27 Merck Hdac Research, Llc Sposób leczenia raka inhibitorami HDAC
CN102349927A (zh) 2003-08-29 2012-02-15 Hdac默克研究有限责任公司 联合治疗癌症的方法
CN100455564C (zh) * 2003-09-12 2009-01-28 深圳微芯生物科技有限责任公司 组蛋白去乙酰化酶抑制剂及其药用制剂的制备和应用
US20070258972A1 (en) * 2003-09-18 2007-11-08 Atadja Peter W Combination of a Histone Deacetylase Inhibitor with a Death Receptor Ligand
EP1673349B1 (en) * 2003-09-22 2010-06-30 S*Bio Pte Ltd Benzimidazole derivatives: preparation and pharmaceutical applications
DE602004027932D1 (de) 2003-09-22 2010-08-12 S Bio Pte Ltd Benzimidazolderivate: herstellung und pharmazeutische anwendungen
EA200600495A1 (ru) * 2003-09-23 2006-10-27 Новартис Аг Комбинация ингибитора vegf рецептора с химиотерапевтическим агентом
WO2005040161A1 (en) * 2003-10-27 2005-05-06 S*Bio Pte Ltd Biaryl linked hydroxamates: preparation and pharmaceutical applications
AU2004296764B2 (en) * 2003-12-02 2011-04-28 The Ohio State University Research Foundation Zn2+ -chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors
EP1541549A1 (en) * 2003-12-12 2005-06-15 Exonhit Therapeutics S.A. Tricyclic hydroxamate and benzaminde derivatives, compositions and methods
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
US20050197336A1 (en) * 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
BRPI0509721A (pt) 2004-04-07 2007-09-25 Novartis Ag inibidores de iap
JP2008506776A (ja) * 2004-07-19 2008-03-06 メルク　エンド　カムパニー　インコーポレーテッド ヒストン脱アセチル化酵素阻害剤
WO2006016680A1 (en) * 2004-08-09 2006-02-16 Astellas Pharma Inc. Hydroxyamide compounds having activity as inhibitors of histone deacetylase (hdac)
ITMI20041869A1 (it) 2004-10-01 2005-01-01 Dac Srl Nuovi inibitori delle istone deacetilasi
US8242175B2 (en) 2004-10-01 2012-08-14 Dac S.R.L. Class of histone deacetylase inhibitors
US7235688B1 (en) 2004-11-04 2007-06-26 University Of Notre Dame Du Lac Process for preparing histone deacetylase inhibitors and intermediates thereof
US20070021612A1 (en) * 2004-11-04 2007-01-25 University Of Notre Dame Du Lac Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US7772245B2 (en) 2005-02-14 2010-08-10 Miikana Therapeutics, Inc. Inhibitors of histone deacetylase
US7666880B2 (en) * 2005-03-21 2010-02-23 S*Bio Pte Ltd. Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications
CA2601706C (en) 2005-03-22 2016-09-20 Dana-Farber Cancer Institute, Inc. Treatment of protein degradation disorders
GB0509225D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
GB0509223D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
TWI365068B (en) 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP1904452A2 (en) * 2005-07-14 2008-04-02 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2007016532A2 (en) * 2005-08-02 2007-02-08 Novartis Ag Mutations and polymorphisms of hdac4
JP5665271B2 (ja) * 2005-08-03 2015-02-04 ノバルティス アーゲー 骨髄腫の処置のためのｈｄａｃ阻害剤の使用
US20090012066A1 (en) * 2005-08-10 2009-01-08 Novartis Ag Method of Use of Deacetylase Inhibitors
WO2007022044A2 (en) * 2005-08-11 2007-02-22 Novartis Ag Combination of organic compounds
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
WO2007022638A1 (en) * 2005-08-26 2007-03-01 Methylgene Inc. Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007030455A2 (en) * 2005-09-07 2007-03-15 Novartis Ag Mutations and polymorphisms of hdac10
WO2007030454A2 (en) * 2005-09-07 2007-03-15 Novartis Ag Mutations and polymorphisms of hdac9
WO2007038073A2 (en) * 2005-09-22 2007-04-05 Novartis Ag Mutations and polymorphisms of hdac11
KR20080054417A (ko) 2005-09-27 2008-06-17 노파르티스 아게 카르복시아민 화합물 및 ｈｄａｃ 의존성 질환의 치료에있어서의 그의 용도
WO2007047998A2 (en) * 2005-10-21 2007-04-26 Novartis Ag Mutations and polymorphisms of hdac2
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
BRPI0617806A2 (pt) * 2005-10-24 2011-08-09 Novartis Ag combinação de inibidores de histona desacetilase com radiação
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
WO2007053502A2 (en) * 2005-11-01 2007-05-10 Novartis Ag Mutations and polymorphisms of hdac5
WO2007058992A2 (en) * 2005-11-14 2007-05-24 Novartis Ag Mutations and polymorphisms of hdac6
ES2481671T3 (es) 2005-11-21 2014-07-31 Novartis Ag Inhibidores de mTOR en el tratamiento de tumores endocrinos
US20070207950A1 (en) * 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
BRPI0707693A2 (pt) 2006-02-07 2011-05-10 Astellas Pharma Inc compostos n-hidroxiacrilamida
CN101400362B (zh) 2006-02-14 2016-10-12 哈佛大学校长及研究员协会 双官能组蛋白去乙酰化酶抑制剂
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
MX2008012715A (es) 2006-04-05 2008-10-14 Novartis Ag Combinaciones de agentes terapeuticos para el tratamiento de cancer.
AU2007234382B2 (en) 2006-04-05 2011-06-09 Novartis Ag Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
EP2450437B1 (en) 2006-04-14 2017-05-17 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
CA2650520A1 (en) 2006-04-24 2008-01-31 Gloucester Pharmaceuticals Treatment of ras-expressing tumors
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
MX2008014292A (es) 2006-05-09 2008-11-18 Novartis Ag Combinacion que comprende un quelante de hierro y un agente anti-neoplastico, y uso de la misma.
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
HRP20130798T1 (en) * 2006-06-12 2013-09-30 Novartis Ag Process for making n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide and starting materials therefor
BRPI0713653A2 (pt) * 2006-06-12 2012-10-23 Novartis Ag processo para a preparação de sais de n-hidróxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil ]fenil]-2e-2propenamida
ES2570934T3 (es) * 2006-06-12 2016-05-23 Novartis Ag Sales de N-hidroxi-3-[4-[[[2-(2-metil-1H-indol-3-il)etil]amino]metil]fenil]-2E-2-propenamida
PH12012501724A1 (en) * 2006-06-12 2014-05-12 Novartis Ag Polymorphs of n-hydroxy3-[4[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]2e-2-propenamide
UA95289C2 (en) * 2006-06-12 2011-07-25 Новартис Аг Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
WO2008002862A1 (en) * 2006-06-26 2008-01-03 Novartis Ag Organic compounds
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008036046A1 (en) 2006-09-20 2008-03-27 S*Bio Pte Ltd IMIDAZO[l,2-a]PYRIDINE HYDROXYMATE COMPOUNDS THAT ARE INHIBITORS OF HISTONE DEACETYLASE
US20100035991A1 (en) * 2006-09-28 2010-02-11 Mckeown Arlene Amide base salts of saha and polymorphis thereof
EP2081933B1 (en) 2006-09-29 2011-03-23 Novartis AG Pyrazolopyrimidines as pi3k lipid kinase inhibitors
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
EA017198B1 (ru) 2006-10-30 2012-10-30 Хрома Терапьютикс Лтд. Гидроксаматы в качестве ингибиторов гистон-деацетилазы
JP2010509370A (ja) * 2006-11-10 2010-03-25 シンダックス ファーマシューティカルズ，インク． 癌の治療用のＥＲα＋リガンドとヒストンデアセチラーゼ阻害剤との組み合わせ
CA2670741C (en) 2006-12-04 2016-04-12 Novartis Ag Combination of an hdac inhibitor and an antimetabolite
WO2008075757A1 (en) * 2006-12-15 2008-06-26 Astellas Pharma Inc. N-hydroxyacrylamide compounds
KR20090098920A (ko) * 2007-01-10 2009-09-17 노파르티스 아게 데아세틸라제 억제제의 제제
JP5693850B2 (ja) * 2007-02-06 2015-04-01 リクスト・バイオテクノロジー，インコーポレイテッド オキサビシクロヘプタンおよびオキサビシクロヘプテン、それらの製造および使用
CA2677651A1 (en) 2007-02-15 2008-08-21 Novartis Ag Combinations of therapeutic agents for treating cancer
CN101646460A (zh) 2007-03-28 2010-02-10 参天制药株式会社 含有具有组蛋白脱乙酰化酶抑制作用的化合物作为有效成分的降眼压剂
EP2139850B1 (en) * 2007-04-09 2018-09-12 MethylGene Inc. Inhibitors of histone deacetylase
MX2009011692A (es) * 2007-05-04 2009-11-10 Novartis Ag Uso de inhibidores de desacetilasa de histona (hdac) para el tratamiento de canceres gastrointestinales.
EP2155193A1 (en) * 2007-05-11 2010-02-24 Novartis Ag Use of hdac inhibitors for the treatment of melanoma
KR101516446B1 (ko) * 2007-05-30 2015-04-30 노파르티스 아게 골 파괴의 치료를 위한 ｈｄａｃ 억제제의 용도
US7737175B2 (en) 2007-06-01 2010-06-15 Duke University Methods and compositions for regulating HDAC4 activity
AU2008284364A1 (en) * 2007-08-03 2009-02-12 Lixte Biotechnology, Inc. Use of phosphatases to treat neuroblastomas and medulloblastomas
CL2008002786A1 (es) * 2007-09-20 2009-05-15 Novartis Ag Torta farmceuticamente aceptable, formada por liofilizacion, que comprende: n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il]-etil]-amino]-metil]-fenil]-2e-2-propenamida o una sal, un regulador de ph seleciondo de lactato o acidop lactico, fodfato o acido fosforico o una combinacion y un agente de volumen; proceso de elaboracion.
EP2200439B1 (en) * 2007-10-01 2017-03-22 Lixte Biotechnology, Inc. Hdac inhibitors
AU2008315651B2 (en) * 2007-10-22 2012-12-13 Orchid Research Laboratories Limited Histone deacetylase inhibitors
CN101417967A (zh) * 2007-10-26 2009-04-29 浙江海正药业股份有限公司 组蛋白去乙酰酶抑制剂、其组合物及其应用
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
WO2009067808A1 (en) * 2007-11-27 2009-06-04 Ottawa Health Research Institute Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors
AU2008350907A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
ITFI20070288A1 (it) 2007-12-21 2009-06-22 A I L Firenze Sezione Autonoma Inibitori delle deacetilasi istoniche
EP2100879A1 (en) * 2008-03-13 2009-09-16 4Sc Ag Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds
KR101673621B1 (ko) 2008-03-24 2016-11-07 노파르티스 아게 아릴술폰아미드-계 매트릭스 메탈로프로테아제 억제제
ES2519474T3 (es) * 2008-03-26 2014-11-07 Novartis Ag Inhibidores de las desacetilasas B basados en hidroxamato
BRPI0915927A2 (pt) * 2008-07-18 2016-06-07 Novartis Ag uso de inibiodores de hdac para o tratamento da doença de hodgkin
WO2010011296A2 (en) 2008-07-23 2010-01-28 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
AU2009277179A1 (en) * 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
US8227473B2 (en) * 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US8058268B2 (en) * 2008-08-01 2011-11-15 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
GB0903480D0 (en) * 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
KR101168801B1 (ko) 2009-03-27 2012-07-25 주식회사종근당 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물
ES2473792T3 (es) 2009-04-03 2014-07-07 Naturewise Biotech & Medicals Corporation Compuestos cin�micos y derivados de los mismos para la inhibición de la histona desacetilasa
US7994357B2 (en) 2009-04-03 2011-08-09 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
US8901337B2 (en) 2009-07-16 2014-12-02 Royal College Of Surgeons In Ireland Metal complexes having dual histone deacetylase inhibitory and DNA-binding activity
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
AU2010284254B2 (en) 2009-08-17 2015-09-17 Intellikine, Llc Heterocyclic compounds and uses thereof
EA201200318A1 (ru) 2009-08-20 2012-09-28 Новартис Аг Гетероциклические оксимы
JP2013503129A (ja) 2009-08-26 2013-01-31 ノバルティス アーゲー テトラ−置換ヘテロアリール化合物ならびにｍｄｍ２および／またはｍｄｍ４モジュレーターとしてのそれらの使用
US20110053925A1 (en) * 2009-08-28 2011-03-03 Novartis Ag Hydroxamate-Based Inhibitors of Deacetylases
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
EP2496575B1 (en) 2009-11-04 2014-04-30 Novartis AG Heterocyclic sulfonamide derivatives useful as mek inhibitors
EA201200617A1 (ru) 2009-11-23 2012-11-30 Серулин Фарма Инк. Полимеры на основе циклодекстрина для доставки лекарственных средств
ES2484171T3 (es) 2009-12-08 2014-08-11 Novartis Ag Derivados de sulfonamidas heterocíclicas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
WO2011084991A2 (en) * 2010-01-08 2011-07-14 President And Fellows Of Harvard College Fluorinated hdac inhibitors and uses thereof
MX341133B (es) 2010-01-13 2016-08-08 Tempero Pharmaceuticals Inc * Compuestos y metodos para la inhibición de hdac.
US8981084B2 (en) 2010-01-13 2015-03-17 Tempero Pharmaceuticals, Inc. Oxadiazole HDAC inhibitors
WO2011090940A1 (en) 2010-01-19 2011-07-28 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
UY33236A (es) 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
US8217079B2 (en) 2010-03-26 2012-07-10 Italfarmaco Spa Method for treating Philadelphia-negative myeloproliferative syndromes
US20110237686A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
EP2407164A1 (en) 2010-07-14 2012-01-18 Dublin Institute of Technology Intellectual Property Ltd Copper II complexes of phenanthroline and their use in cancer treatment
WO2012025701A1 (en) * 2010-08-25 2012-03-01 Chroma Therapeutics Ltd. Alpha, alpha - di substituted glycine ester derivatives and their use as hdac inhibitors
WO2012025155A1 (en) * 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
BR112013004623A2 (pt) * 2010-08-27 2016-07-05 Novartis Ag "inibidores de desacetilases com base em hidroxamato."
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
EP2651917A1 (en) 2010-12-13 2013-10-23 Novartis AG Dimeric iap inhibitors
WO2012097013A1 (en) 2011-01-10 2012-07-19 Nimbus Iris, Inc. Irak inhibitors and uses thereof
TW201245115A (en) 2011-01-24 2012-11-16 Chdi Foundation Inc Histone deacetylase inhibitors and compositions and methods of use thereof
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
CA2828483A1 (en) 2011-02-23 2012-11-01 Intellikine, Llc Combination of kinase inhibitors and uses thereof
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
CN110063951A (zh) 2011-03-09 2019-07-30 赛伦诺科学有限公司 利用组蛋白脱乙酰酶抑制物改善受损的内源纤维蛋白溶解作用的化合物和方法
KR20140034898A (ko) 2011-06-09 2014-03-20 노파르티스 아게 헤테로시클릭 술폰아미드 유도체
EP2720696B1 (en) 2011-06-14 2016-05-25 Novartis AG Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
EP2721007B1 (en) 2011-06-20 2015-04-29 Novartis AG Cyclohexyl isoquinolinone compounds
US8859535B2 (en) 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
SG195067A1 (en) 2011-06-27 2013-12-30 Novartis Ag Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
US12194002B2 (en) 2011-08-17 2025-01-14 Dennis Brown Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
MX354725B (es) 2011-11-11 2018-03-16 Novartis Ag Metodo de tratamiento de una enfermedad proliferativa.
SG11201401260QA (en) 2011-11-23 2014-07-30 Novartis Ag Pharmaceutical formulations
CN103130673B (zh) * 2011-11-28 2017-05-03 重庆医药工业研究院有限责任公司 一种阿戈美拉晶型i的制备方法
EP2785717B1 (en) 2011-11-29 2016-01-13 Novartis AG Pyrazolopyrrolidine compounds
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
WO2013093850A1 (en) 2011-12-22 2013-06-27 Novartis Ag Quinoline derivatives
LT2794600T (lt) 2011-12-22 2018-02-26 Novartis Ag 2,3-dihidro-benzo[1,4]oksazino dariniai ir giminingi junginiai kaip fosfoinozitido-3 kinazės (pi3k) inhibitoriai, skirti gydymui, pavyzdžiui, reumatoidinio artrito
KR20140104047A (ko) 2011-12-23 2014-08-27 노파르티스 아게 Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
EA201491268A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами по связыванию
US20140357633A1 (en) 2011-12-23 2014-12-04 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
EA201491265A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
EA201491259A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами связывания
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
US20150045367A1 (en) * 2011-12-29 2015-02-12 Pharmacyclics, Inc. Cinnamic acid hydroxyamides as inhibitors of histone deacetylase 8
KR102438072B1 (ko) 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
AR092790A1 (es) * 2012-02-01 2015-05-06 Euro Celtique Sa Derivados bencimidazolicos del acido hidroxamico
US20150297604A1 (en) 2012-04-03 2015-10-22 Novartis Ag Combination Products with Tyrosine Kinase Inhibitors and their Use
AP3613A (en) 2012-05-15 2016-02-29 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 abl1abl2 bcr-abl1
ES2665539T3 (es) 2012-05-15 2018-04-26 Novartis Ag Derivados de benzamida para inhibir la actividad de ABL1, ABL2 y BCR-ABL1
JP6078640B2 (ja) 2012-05-15 2017-02-08 ノバルティス アーゲー Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体
WO2013171641A1 (en) 2012-05-15 2013-11-21 Novartis Ag Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1
WO2013175417A1 (en) 2012-05-24 2013-11-28 Novartis Ag Pyrrolopyrrolidinone compounds
US9789193B2 (en) 2012-06-15 2017-10-17 The Brigham And Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
AR091773A1 (es) 2012-07-16 2015-02-25 Chdi Foundation Inc Inhibidores de la histona desacetilasa y composiciones y sus metodos de uso
US9738643B2 (en) 2012-08-06 2017-08-22 Duke University Substituted indazoles for targeting Hsp90
PL3023415T3 (pl) 2012-10-02 2018-06-29 Gilead Sciences, Inc. Inhibitory demetylaz histonowych
WO2014070948A1 (en) 2012-10-30 2014-05-08 Mei Pharma, Inc. Combination therapies
EP3919069A1 (en) 2012-11-05 2021-12-08 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
HK1214765A1 (zh) 2012-11-08 2016-08-05 Novartis Ag 包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
BR112015020650A2 (pt) 2013-02-27 2017-07-18 Epitherapeutics Aps inibidores de histona demetilases
CN105246482A (zh) 2013-03-15 2016-01-13 因特利凯有限责任公司 激酶抑制剂的组合及其用途
WO2014155268A2 (en) 2013-03-25 2014-10-02 Novartis Ag Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
CN105209036B (zh) 2013-04-09 2018-10-26 莱克斯特生物技术公司 氧杂双环庚烷和氧杂双环庚烯的配制品
WO2014178606A1 (en) 2013-04-29 2014-11-06 Chong Kun Dang Pharmaceutical Corp. Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
WO2015013579A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
AU2014321419B2 (en) 2013-09-22 2017-06-15 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
CN103467359B (zh) * 2013-09-27 2015-04-22 山东大学 一种含有吲哚的肉桂酰胺类组蛋白去乙酰化酶抑制剂及其制备方法和应用
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
CN103664734B (zh) * 2013-12-10 2015-09-23 广州康缔安生物科技有限公司 杂环羟肟酸类化合物及其药用组合物和应用
KR101689394B1 (ko) 2013-12-12 2016-12-23 주식회사 종근당 신규한 선택적인 히스톤탈아세틸화 효소 억제제로서의 아자인돌 유도체 및 이를 포함하는 약제학적 조성물
KR101685639B1 (ko) 2014-01-03 2016-12-12 주식회사 종근당 신규한 인돌 유도체 화합물 및 이를 포함하는 약제학적 조성물
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
AU2015222865B2 (en) 2014-02-28 2019-06-20 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
US10000469B2 (en) 2014-03-25 2018-06-19 Duke University Heat shock protein 70 (hsp-70) receptor ligands
EP3122729A4 (en) 2014-03-28 2017-11-15 Calitor Sciences, LLC Substituted heteroaryl compounds and methods of use
CA2943824A1 (en) 2014-03-31 2015-10-08 Gilead Sciences, Inc. Inhibitors of histone demethylases
RU2016140160A (ru) 2014-04-03 2018-05-07 Инвиктус Онколоджи Пвт. Лтд. Супрамолекулярные комбинаторные лекарственные средства
WO2015160845A2 (en) 2014-04-14 2015-10-22 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
JP6526789B2 (ja) 2014-07-31 2019-06-05 ノバルティス アーゲー 組み合わせ療法
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
EP3180349B1 (en) 2014-08-12 2025-03-12 Monash University Lymph directing prodrugs and therapeutic uses thereof
BR112017003442A2 (pt) 2014-08-27 2017-11-28 Gilead Sciences Inc compostos e métodos para inibir histona desmetilases
EP2995630A1 (en) 2014-09-09 2016-03-16 Dublin Institute of Technology Hybrid compounds formed from ionic liquids and uses thereof in ion selective electrodes
EP3191127A1 (en) 2014-09-13 2017-07-19 Novartis AG Combination therapies of egfr inhibitors
EP3200775B1 (en) 2014-10-03 2019-11-20 Novartis AG Combination therapies
KR20250009586A (ko) 2014-10-29 2025-01-17 바이시클러드 리미티드 Mt1-mmp에 특이적인 바이사이클릭 펩타이드 리간드
US20160251376A1 (en) 2015-02-27 2016-09-01 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
HK1247089A1 (zh) 2015-03-10 2018-09-21 Aduro Biotech, Inc. 用於活化“干扰素基因刺激物”依赖性信号传导的组合物和方法
EP3932914A1 (en) 2015-03-13 2022-01-05 Valo Health, Inc. Alpha-cinnamide compounds and compositions as hdac8 inhibitors
US10730870B2 (en) 2015-03-18 2020-08-04 Arvinas Operations, Inc. Compounds and methods for the enhanced degradation of targeted proteins
DK3297992T3 (da) 2015-05-22 2020-04-20 Chong Kun Dang Pharmaceutical Corp Heterocykliske alkylderivatforbindelser som selektive histondeacetylase-inhibitorer og farmaceutiske sammensætninger omfattende samme
WO2017004134A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2017004133A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CA2995036A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
WO2017032281A1 (zh) * 2015-08-21 2017-03-02 苏州晶云药物科技有限公司 帕比司他乳酸盐的新晶型
EP3344624B8 (en) 2015-09-02 2023-11-29 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
CN108137482B (zh) 2015-09-08 2024-03-15 莫纳什大学 定向淋巴的前药
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
ES2941969T3 (es) 2015-10-23 2023-05-29 Navitor Pharm Inc Moduladores de la interacción de Sestrina-GATOR2 y sus usos
CA3002709A1 (en) 2015-11-02 2017-05-11 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
ITUB20155193A1 (it) 2015-11-03 2017-05-03 Italfarmaco Spa Sospensioni orali di Givinostat fisicamente e chimicamente stabili
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017106352A1 (en) 2015-12-14 2017-06-22 Raze Therapeutics, Inc. Caffeine inhibitors of mthfd2 and uses thereof
CA3008272A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3393468B1 (en) 2015-12-22 2022-09-14 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
CN105732467A (zh) * 2016-01-13 2016-07-06 深圳市康立生生物科技有限公司 一种panobinostat(帕比司他)的制备方法
SI3426243T1 (sl) 2016-03-09 2021-11-30 Raze Therapeutics, Inc. Zaviralci 3-fosfoglicerat dehidrogenaze in uporabe le-teh
ES2949357T3 (es) * 2016-03-09 2023-09-28 Raze Therapeutics Inc Inhibidores de 3-fosfoglicerato deshidrogenasa y usos de los mismos
MY197785A (en) 2016-03-15 2023-07-13 Oryzon Genomics Sa Combinations of lsd1 inhibitors for the treatment of hematological malignancies
SG11201807965YA (en) 2016-03-15 2018-10-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017184956A1 (en) 2016-04-22 2017-10-26 Duke University Compounds and methods for targeting hsp90
AR108257A1 (es) 2016-05-02 2018-08-01 Mei Pharma Inc Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
ES2989988T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros heterorocíclicos para la degradación de proteínas diana
US20190330167A1 (en) * 2016-06-21 2019-10-31 The Walter And Eliza Hall Institute Of Medical Research Activators of hiv latency
CN116554168B (zh) 2016-06-21 2025-09-23 X4制药有限公司 Cxcr4抑制剂及其用途
CA3027500A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
WO2018015493A1 (en) 2016-07-20 2018-01-25 Royal College Of Surgeons In Ireland Metal complexes having therapeutic applications
WO2018039203A1 (en) 2016-08-23 2018-03-01 Oncopep, Inc. Peptide vaccines and durvalumab for treating multiple myeloma
WO2018039205A1 (en) 2016-08-23 2018-03-01 Oncopep, Inc. Peptide vaccines and durvalumab for treating breast cancer
WO2018054960A1 (en) 2016-09-21 2018-03-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting and treating resistance to chemotherapy in npm-alk(+) alcl
US10207998B2 (en) 2016-09-29 2019-02-19 Duke University Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
US10927083B2 (en) 2016-09-29 2021-02-23 Duke University Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
WO2018068832A1 (en) 2016-10-11 2018-04-19 Euro-Celtique S.A. Hodgkin lymphoma therapy
IL265922B2 (en) 2016-10-14 2025-02-01 Nimbus Lakshmi Inc TYK2 inhibitors and their uses
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
US10414727B2 (en) 2016-11-08 2019-09-17 Navitor Pharmaceuticals, Inc. Phenyl amino piperidine mTORC inhibitors and uses thereof
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC Exosomes for delivery of therapeutic agents
US11091451B2 (en) 2016-12-05 2021-08-17 Raze Therapeutics, Inc. SHMT inhibitors and uses thereof
CA3046515A1 (en) 2016-12-08 2018-06-14 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
CN110603261A (zh) 2016-12-23 2019-12-20 拜斯科阿迪有限公司 具有新型键结构的肽衍生物
EP3565638B8 (en) 2017-01-06 2024-04-10 BicycleRD Limited Bicycle conjugate for treating cancer
WO2018144649A1 (en) 2017-01-31 2018-08-09 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US11311609B2 (en) 2017-02-08 2022-04-26 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
JP7160824B2 (ja) 2017-03-08 2022-10-25 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤、使用およびその製造のための方法
EP3375784A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aza-dihydro-acridone derivatives
EP3375778A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aryl-piperidine derivatives
US11339144B2 (en) 2017-04-10 2022-05-24 Navitor Pharmaceuticals, Inc. Heteroaryl Rheb inhibitors and uses thereof
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
US10857196B2 (en) 2017-04-27 2020-12-08 Bicycletx Limited Bicyclic peptide ligands and uses thereof
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN107141244B (zh) * 2017-05-08 2019-11-19 潍坊医学院 吲哚丁酸类组蛋白去乙酰酶抑制剂及其制备方法和应用
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
JP7301757B2 (ja) 2017-06-26 2023-07-03 バイスクルアールディー・リミテッド 検出可能部分を持つ二環式ペプチドリガンドおよびその使用
PT3658557T (pt) 2017-07-28 2024-09-11 Nimbus Lakshmi Inc Inibidores de tyk2 e usos dos mesmos
KR101977970B1 (ko) 2017-08-04 2019-05-14 중원대학교 산학협력단 신규한 벤즈아미드계 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 예방 또는 치료용 약학 조성물
CN118772242A (zh) 2017-08-04 2024-10-15 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
US20200291096A1 (en) 2017-08-14 2020-09-17 Bicyclerd Limited Bicyclic peptide ligand sting conjugates and uses thereof
WO2019034868A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
EP3675838A4 (en) 2017-08-29 2021-04-21 PureTech LYT, Inc. LIPID PRODRUGS DIRECTED TO THE LYMPHATIC SYSTEM
MX2020003190A (es) 2017-09-22 2020-11-11 Kymera Therapeutics Inc Degradadores de proteinas y usos de los mismos.
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
EP3461488A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dbait molecule and a hdac inhibitor for treating cancer
EP3700901A1 (en) 2017-10-24 2020-09-02 Genentech, Inc. (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
WO2019083960A1 (en) 2017-10-24 2019-05-02 Oncopep, Inc. PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
AU2018353984A1 (en) 2017-10-24 2020-05-07 Oncopep, Inc. Peptide vaccines and pembrolizumab for treating breast cancer
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
US10683297B2 (en) 2017-11-19 2020-06-16 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
JP7021356B2 (ja) 2017-12-21 2022-02-16 ヘフェイ インスティテューツ オブ フィジカル サイエンス， チャイニーズ アカデミー オブ サイエンシーズ ピリミジン誘導体系キナーゼ阻害剤類
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US10751339B2 (en) 2018-01-20 2020-08-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
US10988477B2 (en) 2018-01-29 2021-04-27 Merck Patent Gmbh GCN2 inhibitors and uses thereof
MX2020007797A (es) 2018-01-29 2020-09-18 Merck Patent Gmbh Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
BR112020016314A2 (pt) 2018-02-12 2020-12-15 Inimmune Corporation Compostos ou um sais farmaceuticamente aceitáveis, composição farmacêutica, kit, e, métodos para elicitar, intensificar ou modificar uma resposta imunológica, para tratar, prevenir ou reduzir a suscetibilidade a câncer, para tratar, prevenir ou reduzir a suscetibilidade a uma doença infecciosa, para tratar, prevenir ou reduzir a suscetibilidade a uma alergia, para tratar, prevenir ou reduzir a suscetibilidade a uma afecção autoimune, para tratar, prevenir ou reduzir a suscetibilidade em um sujeito à infecção bacteriana, viral, priônica, autoimunidade, câncer ou alergia, para tratar, prevenir ou reduzir a suscetibilidade à autoimunidade, alergia, reperfusão de isquemia ou sepse, para tratar, prevenir ou reduzir a gravidade de ataques epiléticos e para tratar, prevenir ou reduzir a suscetibilidade a doenças oculares como degeneração macular, hipertensão ocular e infecção ocular
US10875894B2 (en) 2018-02-23 2020-12-29 Bicycletx Limited Multimeric bicyclic peptide ligands
US10696663B2 (en) 2018-02-27 2020-06-30 Artax Biopharma Inc. Chromene derivatives as inhibitors of TCR-NCK interaction
WO2019183523A1 (en) 2018-03-23 2019-09-26 Genentech, Inc. Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
WO2019199816A1 (en) 2018-04-13 2019-10-17 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
ES2969982T3 (es) 2018-04-24 2024-05-23 Vertex Pharma Compuestos de pteridinona y usos de los mismos
DK3784666T3 (da) 2018-04-24 2022-06-20 Merck Patent Gmbh Antiproliferationsforbindelser og anvendelser deraf
EP3807263A1 (en) 2018-06-13 2021-04-21 Amphista Therapeutics Ltd Bifunctional molecules for targeting uchl5
KR20210021016A (ko) 2018-06-13 2021-02-24 암피스타 테라퓨틱스 엘티디 Rpn11 표적화를 위한 이중작용성 분자
WO2019238886A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting usp14
LT3813946T (lt) 2018-06-15 2024-07-10 Janssen Pharmaceutica Nv Rapamicino analogai ir jų panaudojimas
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
CN108752255A (zh) * 2018-07-19 2018-11-06 重庆医科大学 一种帕比司他及其关键中间体的制备方法
WO2020023628A1 (en) 2018-07-24 2020-01-30 Hygia Pharmaceuticals, Llc Compounds, derivatives, and analogs for cancer
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
JP2022500499A (ja) 2018-09-07 2022-01-04 ピク セラピューティクス， インコーポレイテッド Ｅｉｆ４ｅ阻害剤およびその使用
AU2019360941B2 (en) 2018-10-15 2025-02-27 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
US10919937B2 (en) 2018-10-23 2021-02-16 Bicycletx Limited Bicyclic peptide ligands and uses thereof
CN109574936B (zh) * 2018-11-23 2022-02-22 沈阳药科大学 一种具有hdac6抑制活性的异羟肟酸类化合物及其应用
CA3120866A1 (en) 2018-11-30 2020-06-04 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
EP3886904A4 (en) 2018-11-30 2022-07-13 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
CN113365624A (zh) 2018-12-18 2021-09-07 萌蒂制药国际有限公司 用于治疗淋巴瘤或t-细胞恶性疾病的化合物
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
EP3897849A1 (en) 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
EP3914357A4 (en) 2019-01-23 2022-10-12 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
AU2020253990A1 (en) 2019-04-02 2021-10-28 Bicycletx Limited Bicycle toxin conjugates and uses thereof
CN113939300A (zh) 2019-04-05 2022-01-14 凯麦拉医疗公司 Stat降解剂和其用途
AU2020282759A1 (en) 2019-05-31 2021-12-23 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
US12521438B2 (en) 2019-06-10 2026-01-13 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
GB201913124D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB201913123D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB201913122D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB201913121D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
CA3150492A1 (en) 2019-09-11 2021-03-18 Donna L. Romero USP30 INHIBITORS AND USES THEREOF
MX2022002877A (es) 2019-09-13 2022-08-08 Nimbus Saturn Inc Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
EP3798250A1 (en) 2019-09-25 2021-03-31 University College Dublin Hyperbranched cationic polymers useful as nucleic acid delivery vectors for transfecting
WO2021058492A1 (en) 2019-09-25 2021-04-01 University College Dublin Nanoparticle compositions for gene therapy
AU2020380333A1 (en) * 2019-11-06 2022-04-07 Dana-Farber Cancer Institute, Inc. Selective histone deacetylase (HDAC) degraders and methods of use thereof
CN115209897A (zh) 2019-12-05 2022-10-18 安纳库利亚治疗公司 雷帕霉素类似物及其用途
EP4076520A4 (en) 2019-12-17 2024-03-27 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
CR20220353A (es) 2019-12-19 2022-10-20 Arvinas Operations Inc Compuestos y métodos para la degradación dirigida del receptor de andrógenos
PH12022551522A1 (en) 2019-12-23 2024-01-29 Kymera Therapeutics Inc Smarca degraders and uses thereof
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021159021A1 (en) 2020-02-05 2021-08-12 Puretech Lyt, Inc. Lipid prodrugs of neurosteroids
IT202000004075A1 (it) 2020-02-27 2021-08-27 Flamma Spa Processo per la preparazione di panobinostat
MX2022010944A (es) 2020-03-03 2022-11-09 Pic Therapeutics Inc Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos.
WO2021183650A1 (en) 2020-03-10 2021-09-16 X4 Pharmaceuticals, Inc. Methods for treating neutropenia
WO2021233534A1 (en) 2020-05-20 2021-11-25 Pvac Medical Technologies Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
WO2021185844A1 (en) 2020-03-16 2021-09-23 Pvac Medical Technologies Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
BR112022018678A2 (pt) 2020-03-19 2022-11-01 Kymera Therapeutics Inc Degradadores de mdm2 e usos dos mesmos
EP4136228A4 (en) 2020-04-15 2024-09-11 California Institute of Technology THERMAL REGULATION OF T-CELL IMMUNOTHERAPY BY MOLECULAR AND PHYSICAL ACTUATION
EP4161521A4 (en) 2020-06-03 2024-07-10 Kymera Therapeutics, Inc. DEUTERED IRAQ DEGRADERS AND USES THEREOF
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
EP4192509A1 (en) 2020-08-05 2023-06-14 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
KR20230074721A (ko) 2020-08-17 2023-05-31 바이사이클티엑스 리미티드 Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도
WO2022047259A1 (en) 2020-08-28 2022-03-03 California Institute Of Technology Synthetic mammalian signaling circuits for robust cell population control
CN116601131A (zh) 2020-10-23 2023-08-15 林伯士克洛索有限公司 Ctps1抑制剂及其用途
KR20230131189A (ko) 2020-12-02 2023-09-12 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
AU2021400059A1 (en) 2020-12-18 2023-07-06 Amphista Therapeutics Limited Novel bifunctional molecules for targeted protein degradation
GB202020359D0 (en) 2020-12-22 2021-02-03 Midatech Pharma Wales Ltd Pharmaceutical compositions and use thereof in combination therapy for brain cancer
TW202241891A (zh) 2020-12-30 2022-11-01 美商凱麥拉醫療公司 Irak降解劑及其用途
KR20230153387A (ko) 2021-02-02 2023-11-06 리미널 바이오사이언시스 리미티드 Gpr84 길항제 및 이의 용도
US12378229B2 (en) 2021-02-02 2025-08-05 Liminal Biosciences Limited GPR84 antagonists and uses thereof
CA3207049A1 (en) 2021-02-15 2022-08-18 Jared Gollob Irak4 degraders and uses thereof
MX2023011933A (es) 2021-04-09 2024-01-05 Nimbus Clio Inc Moduladores del linfoma de linaje b de casitas de ligasa e3 b (cbl-b) y usos de estos.
WO2022221866A1 (en) 2021-04-16 2022-10-20 Ikena Oncology, Inc. Mek inhibitors and uses thereof
JP2024519215A (ja) 2021-05-07 2024-05-09 カイメラ セラピューティクス， インコーポレイテッド Ｃｄｋ２分解剤およびそれらの使用
JP2024532276A (ja) 2021-08-25 2024-09-05 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用
US12234231B2 (en) 2021-08-25 2025-02-25 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
WO2023041805A1 (en) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
GB2611043A (en) 2021-09-22 2023-03-29 Univ Dublin City A cis-platinum(II)-oligomer hybrid
TW202334165A (zh) 2021-10-29 2023-09-01 美商凱麥拉醫療公司 Irak4降解劑及其製備
US20250235405A1 (en) 2021-11-19 2025-07-24 Branca Bunus Limited A composition comprising a therapeutically active agent packaged within a drug delivery vehicle
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
IL314437A (en) 2022-01-31 2024-09-01 Kymera Therapeutics Inc IRAK joints and their uses
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
CN119546293A (zh) 2022-04-05 2025-02-28 国家癌症研究所Irccs-G·帕斯卡莱基金会 Hdac抑制剂和他汀类药物的组合用于治疗胰腺癌
GB2617409B (en) 2022-04-27 2024-06-26 Cancertain Ltd Method for predicting responsiveness to therapy
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
AU2023276599A1 (en) 2022-05-25 2024-12-05 Imagenebio, Inc. Mek inhibitors and uses thereof
EP4540226A1 (en) 2022-06-16 2025-04-23 Amphista Therapeutics Ltd Bifunctional molecules for targeted protein degradation
TW202415650A (zh) 2022-08-02 2024-04-16 英商利米那生物科技有限公司 芳基-三唑基及相關gpr84拮抗劑及其用途
WO2024030441A1 (en) 2022-08-02 2024-02-08 National University Corporation Hokkaido University Methods of improving cellular therapy with organelle complexes
WO2024028365A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Substituted pyridone gpr84 antagonists and uses thereof
TW202416950A (zh) 2022-08-02 2024-05-01 英商利米那生物科技有限公司 雜芳基甲醯胺及相關gpr84拮抗劑及其用途
WO2024041744A1 (en) 2022-08-26 2024-02-29 Biodexa Ltd. Combination therapy for brain cancer
WO2024112894A1 (en) 2022-11-22 2024-05-30 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
EP4676454A1 (en) 2023-03-03 2026-01-14 iOnctura SA Combination of roginolisib and hdac inhibitor in the treatment of haematological malignancy
AU2024312190A1 (en) 2023-06-23 2025-07-03 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2025026925A1 (en) 2023-07-28 2025-02-06 Ospedale San Raffaele S.R.L. Gtf2i inhibitors and uses thereof
CN119490449B (zh) * 2023-08-16 2025-11-21 沈阳药科大学 含n-苄基-2-(5-苯基吡啶-2-基)乙酰胺的异羟肟酸类化合物及制备方法和应用
WO2025062372A1 (en) 2023-09-21 2025-03-27 Takeda Pharmaceutical Company Limited Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
WO2025078542A1 (en) 2023-10-11 2025-04-17 Technological University Dublin Coumarin-metal complexes and uses thereof
CN118027033A (zh) * 2024-01-26 2024-05-14 四川大学 一种hdac6抑制剂及其制备方法和在抗炎和溃疡性结肠炎中的用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700811A (en) * 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
DE69221290T2 (de) * 1991-12-10 1998-01-15 Shionogi & Co Auf aromatischen sulfonamiden basierende hydroxamsäurederivate
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
US5569668A (en) * 1995-03-29 1996-10-29 Webster; John M. Indole derivatives with antibacterial and antimycotic properties
US5722242A (en) * 1995-12-15 1998-03-03 Borealis Technical Limited Method and apparatus for improved vacuum diode heat pump
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
JPH10182583A (ja) 1996-12-25 1998-07-07 Mitsui Chem Inc 新規ヒドロキサム酸誘導体
AUPO721997A0 (en) * 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
CN1273579A (zh) 1997-08-05 2000-11-15 美国家用产品公司 氨茴酸类似物
US6127392A (en) * 1997-08-05 2000-10-03 American Home Products Corporation Anthranilic acid analogs
ES2228119T3 (es) 1998-10-19 2005-04-01 Methylgene, Inc. Modulacion de la expresion de la adn-metil-tranferasa mediante terapia de combinacion.
US6110922A (en) 1998-12-29 2000-08-29 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
UA74781C2 (en) 1999-04-02 2006-02-15 Abbott Lab Antiinflammatory and immumosuppressive compounds inhibiting cell adhesion
EA007649B1 (ru) 1999-09-08 2006-12-29 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисёч Ингибиторы гистондеацетилазы, вызывающие дифференцировку клеток, и их применение
GB9922173D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
PT1233958E (pt) * 1999-11-23 2011-09-20 Methylgene Inc Inibidores de histona desacetilase
EP1246905B1 (en) 1999-12-08 2006-03-15 Axys Pharmaceuticals, Inc. Histone deacetylase-8 proteins, nucleic acids, and methods of use
TW427572U (en) * 1999-12-17 2001-03-21 Hon Hai Prec Ind Co Ltd Electrical connector
CA2408385A1 (en) * 2000-03-24 2001-09-24 Methylgene, Inc. Inhibition of specific histone deacetylase isoforms
WO2001070675A2 (en) 2000-03-24 2001-09-27 Methylgene, Inc. Inhibitors of histone deacetylase
EP1314721A1 (en) * 2000-08-31 2003-05-28 Wakunaga Pharmaceutical Co., Ltd. Novel propenohydroxamic acid derivatives
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
JP2004510763A (ja) 2000-10-05 2004-04-08 藤沢薬品工業株式会社 アポｂ分泌阻害剤としてのベンズアミド化合物
SE0101386D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab New compounds
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
EP1417169A2 (en) 2001-08-11 2004-05-12 Bristol-Myers Squibb Pharma Company Selective estrogen receptor modulators
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
DE10152764A1 (de) * 2001-10-29 2003-05-08 Linde Ag Ventil für kryogene Medien

Also Published As

Publication number Publication date
US6833384B2 (en) 2004-12-21
NO2015026I2 (no) 2015-12-28
TWI286544B (en) 2007-09-11
SI1318980T1 (sl) 2008-08-31
ES2292610T3 (es) 2008-03-16
HUP0300880A2 (hu) 2003-08-28
US20030018062A1 (en) 2003-01-23
AU8212901A (en) 2002-03-26
HUP0300880A3 (en) 2010-03-29
DE60131179T2 (de) 2008-03-06
CZ2003573A3 (cs) 2003-06-18
JP2004509105A (ja) 2004-03-25
PL361408A1 (en) 2004-10-04
US20080176849A1 (en) 2008-07-24
EP1318980B1 (en) 2007-10-31
MXPA03001832A (es) 2003-06-04
CY2015053I2 (el) 2016-06-22
ECSP034492A (es) 2003-04-25
FR15C0086I1 (cg-RX-API-DMAC10.html) 2016-01-15
LU92890I2 (fr) 2016-02-01
EP1318980A2 (en) 2003-06-18
BRPI0113669B8 (pt) 2021-05-25
PL221738B1 (pl) 2016-05-31
EP1870399A1 (en) 2007-12-26
CA2420899C (en) 2011-03-08
AR035057A1 (es) 2004-04-14
NO2015026I1 (no) 2015-12-10
RU2302408C2 (ru) 2007-07-10
CZ302707B6 (cs) 2011-09-14
CN1300110C (zh) 2007-02-14
MY136892A (en) 2008-11-28
CA2420899A1 (en) 2002-03-21
CY1107839T1 (el) 2013-06-19
US20060189674A1 (en) 2006-08-24
PE20020354A1 (es) 2002-06-12
CY2015053I1 (el) 2016-06-22
HUS1500068I1 (hu) 2018-05-02
US6552065B2 (en) 2003-04-22
HK1057746A1 (en) 2004-04-16
NL300778I2 (cg-RX-API-DMAC10.html) 2016-06-30
IL154574A0 (en) 2003-09-17
ZA200301423B (en) 2004-04-21
ATE376999T1 (de) 2007-11-15
WO2002022577A2 (en) 2002-03-21
BE2015C062I2 (cg-RX-API-DMAC10.html) 2021-01-28
DE60131179D1 (en) 2007-12-13
RU2302408C3 (ru) 2018-06-01
US20050085507A1 (en) 2005-04-21
NO20030867D0 (no) 2003-02-25
SK2422003A3 (en) 2003-09-11
BRPI0113669B1 (pt) 2017-06-06
NZ524365A (en) 2004-11-26
US7067551B2 (en) 2006-06-27
KR100585484B1 (ko) 2006-06-07
CN1450991A (zh) 2003-10-22
KR20030031986A (ko) 2003-04-23
SK287609B6 (sk) 2011-04-05
DK1318980T3 (da) 2008-02-11
WO2002022577A3 (en) 2002-09-06
NO324942B1 (no) 2008-01-07
HU229796B1 (en) 2014-07-28
AU2001282129B2 (en) 2005-08-25
NO20030867L (no) 2003-02-25
PT1318980E (pt) 2008-01-17
BR0113669A (pt) 2003-06-03
US20040024067A1 (en) 2004-02-05
FR15C0086I2 (fr) 2016-06-03
IL154574A (en) 2010-02-17

Similar Documents

Publication Publication Date Title
JP4012819B2 (ja) デアセチラーゼ阻害剤として有用なヒドロキサム酸誘導体
AU2001282129A1 (en) Hydroxamate derivatives useful as deacetylase inhibitors
PL205853B1 (pl) Kombinacja zawierająca inhibitor COX-2 oraz inhibitor deacetylazy histonów, kompozycja farmaceutyczna zawierająca inhibitor COX-2 oraz inhibitor deacetylazy histonów, zastosowanie tej kombinacji oraz opakowanie handlowe lub produkt handlowy obejmujący inhibitor COX -2 oraz inhibitor deacetylazy histonów
CN113387938A (zh) 一种取代嘧啶类化合物、其制备方法、中间体及应用
JP2009504656A (ja) デアセチラーゼ阻害剤の使用法
CN101253167A (zh) 作为ksp抑制剂的取代的咪唑化合物
WO2023061368A1 (zh) 一类羟肟酸衍生物及其应用
HK1057746B (en) Hydroxamate derivatives useful as deacetylase inhibitors
CN111548286B (zh) 一种具有hdac3抑制活性的psa衍生物及其应用
WO2025242233A1 (zh) 一种酰胺吲嗪类化合物及其制备方法和应用
CN102336740B (zh) 一类咪唑类化合物及其用途
JP2010526149A (ja) 消化管がんの処置のためのｈｄａｃ阻害剤の使用

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070501

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20070510

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20070726

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20070904

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20070910

R150 Certificate of patent or registration of utility model

Ref document number: 4012819

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100914

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100914

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110914

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120914

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130914

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250